Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 6/2003

01-10-2003

The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells

Authors: Åse Bratland, Erlend Ragnhildstveit, Kristin Bjørnland, Kristin Andersen, Gunhild Mari Mælandsmo, Øystein Fodstad, Fahri Saatcioglu, Anne Hansen Ree

Published in: Clinical & Experimental Metastasis | Issue 6/2003

Login to get access
Metadata
Title
The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
Authors
Åse Bratland
Erlend Ragnhildstveit
Kristin Bjørnland
Kristin Andersen
Gunhild Mari Mælandsmo
Øystein Fodstad
Fahri Saatcioglu
Anne Hansen Ree
Publication date
01-10-2003
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 6/2003
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1025860214891

Other articles of this Issue 6/2003

Clinical & Experimental Metastasis 6/2003 Go to the issue

OriginalPaper

Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis

OriginalPaper

Role of insulin-like growth factor binding proteins (IGFBPs) in breast cancer proliferation and metastasis

OriginalPaper

Detection of disseminated tumor cells in nude mice with human gastric cancer

OriginalPaper

Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor

OriginalPaper

The role of Bcl-2 family members in the progression of cutaneous melanoma

OriginalPaper

Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits